References
- Worrall G. Bronchiolitis. Can Fam Physician [Internet]. 2008 May;54(5):742–743. [cited 2018 Jan 7] Available from: http://www.ncbi.nlm.nih.gov/pubmed/18474710
- Geoghegan S, Erviti A, Caballero MT, et al. Mortality due to respiratory syncytial virus. burden and risk factors. Am J Respir Crit Care Med [Internet]. 2017 Jan 1 ;195(1):96–103. [cited 2017 Nov 2] Available from: http://www.ncbi.nlm.nih.gov/pubmed/27331632
- Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet [Internet]. 2012 Dec 15 ;380(9859):2095–2128. cited 2017 Nov 2 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23245604
- Gong C, Byczkowski T, McAneney C, et al. Emergency department management of bronchiolitis in the United States. Pediatr Emerg Care [Internet]. 2017 Apr24cited 2017 Nov 21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28441240
- Fauroux B, Simões EAF, Checchia PA, et al. The burden and long-term respiratory morbidity associated with respiratory syncytial virus infection in early childhood. Infect Dis Ther [Internet]. 2017 Jun 29 [cited 2018 Jan 20];6(2):173–197.
- Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics [Internet]. 2014 Nov 1 ;134(5):e1474–502. [cited 2017 Nov 2] Available from: http://www.ncbi.nlm.nih.gov/pubmed/25349312
- Resch B. Respiratory syncytial virus infection in high-risk infants – an update on palivizumab prophylaxis. Open Microbiol J [Internet]. 2013 Jul 11 [cited 2018 Jan 20];8(1):71–77. Available from: http://benthamopen.com/ABSTRACT/TOMICROJ-8-71
- Scheltema NM, Gentile A, Lucion F, et al. Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series. Lancet Glob Heal [Internet]. 2017 Oct cited 2018 Jan 5;5(10):e984–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28911764
- Bont L, Checchia PA, Fauroux B, et al. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in Western Countries. Infect Dis Ther. 2016;5(3):271–298.
- Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med [Internet]. 2009 Feb 5;360(6):588–598. [cited 2018 Jan 7]
- Zhang S, Sammon PM, King I, et al. Cost of management of severe pneumonia in young children: systematic analysis. J Glob Health [Internet]. 2016 Jun ;6(1):010408. [cited 2018 July 3] Available from: http://www.ncbi.nlm.nih.gov/pubmed/27231544
- Chan PWK, Abdel-Latif MEA. Cost of hospitalization for respiratory syncytial virus chest infection and implications for passive immunization strategies in a developing nation. Acta Paediatr [Internet]. 2003 April [cited 2018 July 3];92(4):481–485. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12801117
- Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr [Internet]. 2003 Nov [cited 2018 Jul 3];143(5 Suppl):S127–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14615711
- Gamiño-Arroyo AE, Moreno-Espinosa S, Llamosas-Gallardo B, et al. Epidemiology and clinical characteristics of respiratory syncytial virus infections among children and adults in Mexico. Influenza Other Respi Viruses. 2017;11(1):48–56.
- Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet (London, England) [Internet]. 2017 Sep 2 ;390(10098):946–958. cited 2018 Jan 5 Available from: http://linkinghub.elsevier.com/retrieve/pii/S0140673617309388
- Nicolai A, Ferrara M, Schiavariello C, et al. Viral bronchiolitis in children: A common condition with few therapeutic options. Early Hum Dev [Internet]. 2013 Oct;89:S7–11. cited 2018 Jul 3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23972293
- Øymar K, Skjerven H, Mikalsen I. Acute bronchiolitis in infants, a review. Scand J Trauma Resusc Emerg Med [Internet]. 2014 Apr 3 [cited 2018 Jul 3;22(1):23. DOI: 10.1186/1757-7241-22-23
- Hancock DG, Charles-Britton B, Dixon D-L, et al. The heterogeneity of viral bronchiolitis: A lack of universal consensus definitions. Pediatr Pulmonol [Internet]. 2017 Sep [cited 2018 Jun 25];52(9):1234–1240. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28672069
- Megalaa R, Perez GF, Kilaikode-Cheruveettara S, et al. Clinical definition of respiratory viral infections in young children and potential bronchiolitis misclassification. J Investig Med [Internet]. 2018;66(1):46–51. cited 2018 Jun 22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28947640
- Villafana T, Falloon J, Griffin MP, et al. Passive and active immunization against respiratory syncytial virus for the young and old. Expert Rev Vaccines [Internet]. 2017 Jul 3 [cited 2017 Oct 17];16(7):737–749.
- Giersing BK, Karron RA, Vekemans J, et al. Meeting report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine development, Geneva, 25–26 April 2016. Vaccine [Internet]. 2017 Mar 14. [cited 2018 Jul 3]. Available from: https://www.sciencedirect.com/science/article/pii/S0264410X17302931
- Smyth RL, Openshaw PJM. Bronchiolitis. Lancet (London, England) [Internet]. 2006 Jul 22 cited 2018 Jul 3;368(9532):312–322. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16860701
- ``Florin TA, Plint AC, Zorc JJ. Viral bronchiolitis. Lancet (London, England) [Internet]. 2017 Jan 14;389(10065):211–224. [cited 2018 Jul 3]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27549684
- Meissner HC. Viral bronchiolitis in children. N Engl J Med [Internet]. Ingelfinger JR, editor. . 2016 Jan 7 [cited 2018 Jul 3];374(1):62–72. Available from: http://www.nejm.org/doi/10.1056/NEJMra1413456
- Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev [Internet]. 2014 Jun 17;(6):CD001266. [cited 2018 Apr 3]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24937099
- McNamara PS, Smyth RL. The pathogenesis of respiratory syncytial virus disease in childhood. Br Med Bull [Internet]. 2002 Mar 1 [cited 2018 Jul 4];61(1):13–28.
- Eiland LS. Respiratory syncytial virus: diagnosis, treatment and prevention. J Pediatr Pharmacol Ther [Internet]. 2009 Apr [cited 2018 Jan 20];14(2):75–85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23055894
- Tregoning JS, Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev [Internet]. 2010 Jan [cited 2018 Jan 22];23(1):74–98. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20065326
- Borchers AT, Chang C, Gershwin ME, et al. Respiratory syncytial virus—a comprehensive review. Clin Rev Allergy Immunol [Internet]. 2013 Dec 12 cited 2018 Jan 22;45(3):331–379. Available from: http://link.springer.com/10.1007/s12016-013-8368-9
- Schroeder AR, Mansbach JM, Stevenson M, et al. Apnea in children hospitalized with bronchiolitis. Pediatrics [Internet]. 2013 Nov ;132(5):e1194–201. cited 2018 Jan 22 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24101759
- Clinical practice guideline on acute bronchiolitis. [cited 2017 Nov 2]; Available from: http://www.guiasalud.es/GPC/GPC_475_Bronchiolitis_AIAQS_compl_en.pdf
- NICE. Bronchiolitis in children : diagnosis and management. 2015;(June):1–30. Available from: https://www.nice.org.uk/guidance/ng9.
- Wright M, Mullett CJ, Piedimonte G. Pharmacological management of acute bronchiolitis. Ther Clin Risk Manag [Internet]. 2008 Oct [cited 2018 Jul 5];4(5):895–903. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19209271
- Mussman GM, Parker MW, Statile A, et al. Suctioning and length of stay in infants hospitalized with bronchiolitis. JAMA Pediatr [Internet]. 2013 May 1 cited 2017 Nov 2;167(5):414. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23460088
- Turnham H, Agbeko RS, Furness J, et al. Non-invasive respiratory `support for infants with bronchiolitis: a national survey of practice. BMC Pediatr [Internet]. 2017 Jan 17 cited 2017 Nov 2;17(1):20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28095826
- Drysdale SB, Green CA, Sande CJ. Best practice in the prevention and management of paediatric respiratory syncytial virus infection. Ther Adv Infect Dis. 2016 Apr;3(2):63–67.
- Lorente S, Gimeno R, Losilla JM, et al. Benefits of the humidified low-flow oxygen therapy in infants with mild-moderate bronchiolitis. J Clin Nurs [Internet]. 2017; Oct27 [cited 2017 Nov 2] DOI: 10.1111/jocn.14140.
- Essouri S, Baudin F, Chevret L, et al. Variability of care in infants with severe bronchiolitis: less-invasive respiratory management leads to similar outcomes. J Pediatr [Internet]. 2017 Sep [cited 2017 Nov 2];188:156–162.e1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28602381
- Beggs S, Wong ZH, Kaul S, et al. High-flow nasal cannula therapy for infants with bronchiolitis. In: Beggs S, editor. Cochrane database of systematic reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2014. CD009609. [cited 2017 Nov 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24442856
- Pedersen MB, Vahlkvist S.Comparison of CPAP and HFNC in management of bronchiolitis in infants and young children. Children [Internet] 2017;Apr 20 cited 2017 Nov 24(4)28. Available from: http://www.mdpi.com/2227-9067/4/4/28
- Essouri S, Baudin F, Chevret L, et al.. variability of care in infants with severe bronchiolitis: less-invasive respiratory management leads to similar outcomes. J Pediatr. 2017;188:156–162.
- Pedersen MB, Vahlkvist S. Comparison of CPAP and HFNC in management of bronchiolitis in infants and young children. Child (Basel, Switzerland) [Internet]. 2017 Apr 20;4(4). [cited 2018 Jan 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28425965
- Milési C, Essouri S, Pouyau R, et al. High flow nasal cannula (HFNC) versus nasal continuous positive airway pressure (nCPAP) for the initial respiratory management of acute viral bronchiolitis in young infants: a multicenter randomized controlled trial (TRAMONTANE study). Intensive Care Med [Internet]. 2017 Feb 26;43(2):209–216. [cited 2018 Jan 5];
- Kepreotes E, Whitehead B, Attia J, et al. High-flow warm humidified oxygen versus standard low-flow nasal cannula oxygen for moderate bronchiolitis (HFWHO RCT): an open, phase 4, randomised controlled trial. Lancet (London, England) [Internet]. 2017 Mar 4 ;389(10072):930–939. [cited 2018 Jan 19] Available from: http://www.ncbi.nlm.nih.gov/pubmed/28161016
- Kennedy N, Flanagan N. Is nasogastric fluid therapy a safe alternative to the intravenous route in infants with bronchiolitis? Arch Dis Child [Internet]. 2005 Mar 1 cited 2018 Jan 19;90(3):320–321. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15723931
- Oakley E, Borland M, Neutze J, et al. Nasogastric hydration versus intravenous hydration for infants with bronchiolitis: a randomised trial. Lancet Respir Med [Internet]. 2013 Apr ;1(2):113–120. [cited 2018 Jan 19] Available from: http://www.ncbi.nlm.nih.gov/pubmed/24429091
- Wang J, Xu E, Xiao Y. Isotonic versus hypotonic maintenance iv fluids in hospitalized children: a meta-analysis. Pediatrics [Internet]. 2014 Jan 30 [cited 2018 Jan 19];133(1):105–113. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24379232
- Roqué I Figuls M, Giné-Garriga M, Granados Rugeles C, et al. Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old. In: Vilaró J, editor. Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2016. CD004873. [cited 2017 Nov 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26833493
- Van Ginderdeuren F, Vandenplas Y, Deneyer M, et al. Influence of bouncing and assisted autogenic drainage on acid gastro-oesophageal reflux in infants. Pediatric Pulmonology. 2017 Aug 1 [cited 2018 Jan 11];52(8):1057–1062.
- Luginbuhl LM, Newman TB, Pantell RH, et al. Office-based treatment and outcomes for febrile infants with clinically diagnosed bronchiolitis. Pediatrics [Internet]. 2008 Nov 1 cited 2018 Jan 23;122(5):947–954. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6129609
- Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. In: Gadomski AM, editor. Cochrane database of systematic reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2014. CD001266. [cited 2017 Nov 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24937099
- Hartling L, Bialy LM, Vandermeer B, et al. Epinephrine for bronchiolitis. In: Hartling L, editor. Cochrane database of systematic reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2011. cited 2017 Nov 2;CD003123. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21678340
- Schroeder AR, Mansbach JM. Recent evidence on the management of bronchiolitis. Curr Opin Pediatr [Internet]. 2014 Jun [cited 2018 Jul 3];26(3):328–333. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24739493
- Rjpg C, Seddon P, Bara A, et al. Short acting beta2-agonists for recurrent wheeze in children under two years of age (Review) Short acting beta2-agonists for recurrent wheeze in children under two years of age. Clin Trials. 2009(1):2–4
- Everard M, Bara A, Kurian M, et al. Anticholinergic drugs for wheeze in children under the age of two years. In: Mayowe V, editor. Cochrane database of systematic reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2005. CD001279. [cited 2018 Jan 22]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16034861
- Kan RX, Zhang CL, Zhen Q, et al. Magnesium sulfate micro air pump suction for bronchiolitis treatment in infants under two years old. Eur Rev Med Pharmacol Sci. 2016;20(6):1180–1184.
- Modaresi MR, Faghihinia J, Kelishadi R, et al. Erratum to: nebulized magnesium sulfate in acute bronchiolitis: a randomized controlled trial (indian j pediatr, 82, 9(794-798), doi:10.1007/s12098-015-1729-z). Indian J Pediatr [Internet]. 2016;83(5):487.
- Alansari K, Sayyed R, Davidson BL, et al. IV Magnesium Sulfate for Bronchiolitis: A Randomized Trial. Chest [Internet]. 2017;1521:113–119. DOI: 10.1016/j.chest.2017.03.002
- Hossny E, Rosario N, Lee BW, et al. The use of inhaled corticosteroids in pediatric asthma: update. World Allergy Organ J [Internet]. 2016 [cited 2018 Jan 8];9:26. Available from http://www.ncbi.nlm.nih.gov/pubmed/27551328
- Cutrera R, Baraldi E, Indinnimeo L, et al. Management of acute respiratory diseases in the pediatric population: the role of oral corticosteroids. Ital J Pediatr [Internet]. 2017 Mar 23 ;43(1):31. [cited 2018 Jan 3] Available from: http://www.ncbi.nlm.nih.gov/pubmed/28335827
- Fernandes RM, Bialy LM, Vandermeer B, et al. Glucocorticoids for acute viral bronchiolitis in infants and young children. In: Fernandes RM, editor. Cochrane Database Syst Rev. 2010 Oct 6;(10):CD004878. doi: 10.1002/14651858.CD004878.pub3
- Zhang L, Mendoza-Sassi RA, Wainwright C, et al. Nebulised hypertonic saline solution for acute bronchiolitis in infants. In: Zhang L, editor. Cochrane database of systematic reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2013. CD006458. [cited 2017 Nov 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23900970
- Zhang L, Mendoza-Sassi RA, Wainwright C, et al. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev [Internet]. 2013;(12). DOI: 10.1002/14651858.CD006458.pub3
- Kua KP, Lee SWH. Systematic review and meta-analysis of the efficacy and safety of combined epinephrine and corticosteroid therapy for acute bronchiolitis in infants. Front Pharmacol [Internet]. 2017 Jun 22;8:396. [cited 2018 Jan 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28690542
- Liu F, Ouyang J, Sharma AN, et al. Leukotriene inhibitors for bronchiolitis in infants and young children. In: Liu S, editor. Cochrane database of systematic reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2015. cited 2017 Nov 2;CD010636. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25773054
- Farley R, Spurling GK, Eriksson L, et al. Antibiotics for bronchiolitis in children under two years of age. In: Spurling GK, editor. Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2014. CD005189. [cited 2018 Jan 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25300167
- Lehtinen P, Jartti T, Virkki R, et al. Bacterial coinfections in children with viral wheezing. Eur J Clin Microbiol Infect Dis [Internet]. 2006 Jul 4 [cited 2018 Jan 5];25(7):463–469.
- Farley R, Spurling GK, Eriksson L, et al. Antibiotics for bronchiolitis in children under two years of age. In: Spurling GK, editor. Cochrane database of systematic reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2014. CD005189. [cited 2017 Nov 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25300167
- Gupta VK, Cheifetz IM. Heliox administration in the pediatric intensive care unit: an evidence-based review. Pediatr Crit Care Med [Internet]. 2005 Mar [cited 2018 Jan 11];6(2):204–211. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15730610
- Papamoschou D. Theoretical validation of the respiratory benefits of helium-oxygen mixtures. Respir Physiol. Internet]. 1995 Jan 1 [cited 2018 Jan 11];99(1):183–190. Available from: http://www.sciencedirect.com/science/article/pii/0034568794000717?via%3Dihub
- Liet J-M, Ducruet T, Gupta V, et al. Heliox inhalation therapy for bronchiolitis in infants. In: J-M L, editor. Cochrane database of systematic reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2015. CD006915. [cited 2018 Jan 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26384333
- Liet J-M, Ducruet T, Gupta V, et al. Heliox inhalation therapy for bronchiolitis in infants. In: Liet J-M, editor. Cochrane database of systematic reviews. Chichester, UK: John Wiley & Sons, Ltd; 2015. p. CD006915.
- Eber E. Treatment of acute viral bronchiolitis. Open Microbiol J [Internet]. 2011 Dec 30 cited 2018 Jan 5;5(1):159–164. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22262989
- Jat KR, Chawla D. Surfactant therapy for bronchiolitis in critically ill infants. In: Jat KR, editor. Cochrane database of systematic reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2015. CD009194. [cited 2017 Nov 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26299681
- Schroeder AR, Mansbach JM, Stevenson M, et al. Apnea in children hospitalized with bronchiolitis. Pediatrics [Internet]. 2013 Nov 1 ;132(5):e1194–201. cited 2018 Jan 23 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24101759
- Baraldi E, Lanari M, Manzoni P, et al. Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants. Ital J Pediatr [Internet]. 2014 Oct24 ;40:65. cited 2017 Nov 2 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25344148
- Ramesh P. Are methylxanthines effective in preventing or reducing apnoeic spells in infants with bronchiolitis? Arch Dis Child [Internet]. 2005 Mar 1 [cited 2017 Nov 2];90(3):321–322.
- Kua KP, Lee SWH, Complementary and alternative medicine for the treatment of bronchiolitis in infants: A systematic review. Hartling L, editor. PLoS One [Internet]. 2017 Feb 17; 12(2): e0172289. [cited 2017 Nov 2]; DOI: 10.1371/journal.pone.0172289
- Merkus PJ, de Hoog M, van Gent R, et al. DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis. Eur Respir J [Internet]. 2001;18(4):734–737. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=11716180
- Heylen E, Neyts J, Jochmans D. Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery. Biochem Pharmacol [Internet]. 2017 Mar 1;127:1–12. [cited 2018 Jan 23]. Available from: https://www.sciencedirect.com/science/article/pii/S0006295216302970
- Tuschl T, Zamore PD, Lehmann R, et al. Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev [Internet]. 1999 Dec 15 cited 2018 Jan 6;13(24):3191–3197. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10617568
- Olszewska W, Openshaw P. Emerging drugs for respiratory syncytial virus infection. Expert Opin Emerg Drugs [Internet]. 2009 Jun [cited 2018 Jan 6];14(2):207–217. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19453286
- Beaucourt S, Vignuzzi M. Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance. Curr Opin Virol [Internet]. 2014 Oct 1;8:10–15. [cited 2018 Jan 20]. Available from: https://www.sciencedirect.com/science/article/pii/S1879625714000935
- Schweitzer JW, Justice NA. Respiratory Syncytial Virus Infection (RSV) [Internet]. StatPearls. StatPearls Publishing, Treasure Island (FL); 2017. [cited 2017 Nov 11]. Available from http://www.ncbi.nlm.nih.gov/pubmed/29083623
- Neuzil KM. Progress toward a respiratory syncytial virus vaccine. Clin Vaccine Immunol [Internet]. 2016 Jan 27 cited 2018 Jan 6;23(3):186–188. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26818954
- Turner TL, Kopp BT, Paul G, et al. Respiratory syncytial virus: current and emerging treatment options. Clinicoecon Outcomes Res [Internet]. 2014 [cited 2018 Jan 20];6:217–225. Available from http://www.ncbi.nlm.nih.gov/pubmed/24812523
- Ventre K, Randolph A. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. In: Ventre K, editor. Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2010. CD000181. [cited 2018 Jan 20]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20464715
- McCoy D, Wong E, Kuyumjian AG, et al. Treatment of respiratory syncytial virus infection in adult patients with hematologic malignancies based on an institution-specific guideline. Transpl Infect Dis [Internet]. 2011 Apr [cited 2018 Jan 20];13(2):117–121. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20804534
- Friedman JN, Rieder MJ, Walton JM. Bronchiolitis: recommendations for diagnosis, monitoring and management of children one to 24 months of age. Paediatr Child Health [Internet]. 2014 Nov 1 cited 2017 Nov 2;19(9):485–491. Available from: https://academic.oup.com/pch/article-lookup/doi/10.1093/pch/19.9.485
- Y-I K, Pareek R, Murphy R, et al. The antiviral effects of RSV fusion inhibitor, MDT-637, on clinical isolates, vs its achievable concentrations in the human respiratory tract and comparison to ribavirin. Influenza Other Respi Viruses [Internet]. cited 2017 Nov 11 2017 Oct 30. DOI: 10.1111/irv.12503
- Fearns R, Deval J. New antiviral approaches for respiratory syncytial virus and other mononegaviruses: inhibiting the RNA polymerase. Antiviral Res [Internet]. 2016 Oct 1;134:63–76. [cited 2018 Jan 20]. Available from: https://www.sciencedirect.com/science/article/pii/S0166354216303527
- Mackman RL, Sangi M, Sperandio D, et al. Fusion inhibitor (GS-5806) and clinical proof of concept in a human rsv challenge study. J Med Chem. 2015 Feb 26;58(4):1630-1643
- Kim Y-I, Pareek R, Murphy R, et al. The antiviral effects of RSV fusion inhibitor, MDT-637, on clinical isolates, versus its achievable concentrations in the human respiratory tract and comparison to ribavirin. Influenza Other Respir Viruses. 2017 Nov;11(6):525–530.
- Caballero MT, Polack FP, Stein RT, Viral bronchiolitis in young infants: new perspectives for management and treatment. J Pediatr (Rio J) [Internet]. 2017. ARTICLE IN PRESS +Model. Available from. www.jped.com.br
- Rodriguez WJ, Gruber WC, Welliver RC, et al. Respiratory Syncytial Virus (RSV) Immne Globulin Intravenous Therapy for RSV Lower Respiratory Tract Infection in Infants and Young Children at High Risk for Severe RSV Infections. Pediatrics [Internet]. 1997 Mar 1 ;99(3):454–461. cited 2018 Feb 5 Available from: http://www.ncbi.nlm.nih.gov/pubmed/9041304
- Bouthillier MJ. RespiGam/PREVENT study questioned. Pediatrics. 1997 Aug cited 2018 Feb 5;100(2 Pt 1):275–276. Internet. Available from http://www.ncbi.nlm.nih.gov/pubmed/9254383
- Krilov LR. Respiratory syncytial virus disease: update on treatment and prevention. Expert Rev Anti Infect Ther [Internet]. 2011 Jan 10 cited 2018 Feb 5;9(1):27–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21171875
- Schroeder AR, Mansbach JM. Recent evidence on the management of bronchiolitis. Curr Opin Pediatr. 2014 Jun;26(3):328–333.
- Schlapbach LJ, Straney L, Gelbart B, et al. Burden of disease and change in practice in critically ill infants with bronchiolitis. Eur Respir J. 2017 Jun 1;49(6):1601648.
- Zhu Q, McLellan JS, Kallewaard NL, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med [Internet]. 2017 May 3 ;9(388):eaaj1928. cited 2017 Nov 2 Available from: http://www.ncbi.nlm.nih.gov/pubmed/28469033
- Respiratory syncytial virus green book chapter 27a v2_0 27a Respiratory syncytial virus. 2015 [cited 2018 Feb 5]; Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/458469/Green_Book_Chapter_27a_v2_0W.PDF
- Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol [Internet]. 2007 May 4 ;368(3):652–665. cited 2018 Jan 11 Available from: http://www.sciencedirect.com/science/article/pii/S0022283607002057?via%3Dihub
- Lagos R, Devincenzo JP, Muñoz A, et al. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)- specific humanized monoclonal antibody, when administered to RSV-infected children. Pediatr Infect Dis J. 2009;28(9):835–837.
- Carbonell-Estrany X, Simoes EAF, Dagan R, et al. Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial. Pediatrics [Internet]. 2010;125(1):e35–51. Available from: 10.1542/peds.2008-1036
- Robbie GJ, Criste R, Dall’acqua WF, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother [Internet]. 2013 Dec 1 ;57(12):6147–6153. cited 2018 Jan 11 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24080653
- Study to evaluate the efficacy and safety of REGN2222, for the prevention of medically attended rsv (respiratory syncytial virus) infection in preterm infants - full text view - clinicaltrials.gov [Internet]. [cited 2018 Jan 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT02325791
- Regeneron to discontinue development of suptavumab for respiratory syncytial virus (NASDAQ:REGN) [Internet]. [cited 2018 Jan 6]. Available from: http://investor.regeneron.com/releaseDetail.cfm?releaseid=1037184
- Mejias A, Garcia-Maurino C, Rodriguez-Fernandez R, et al. Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection. Vaccine [Internet]. 2017 Jan 11;35(3):496–502. [cited 2018 Jan 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27692523
- J. F go. [Internet]. SS (MD): USD of H and HSC 2016 S 29. No Title.
- Wasserman RL, Greener BN, Mond J. RI002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations. Expert Rev Clin Immunol [Internet]. 2017 Dec 2 cited 2018 Jan 11;13(12):1107–1119. doi:10.1080/1744666X.2017.1389647
- Falsey AR, Walsh EE, Mond JJ Polyclonal Human Intravenous Immune Globulin (IGIV) with High-Levels of RSV Neutralizing Antibodies: A summary of animal and human studies. [cited 2018 Jul 4]; Available from: https://d1io3yog0oux5.cloudfront.net/_fc2ccd522b929e25df2ab17869add49b/admabiologics/db/149/1718/file/CMBT+2014-Updated+09302015.pdf
- Falsey A, Koval C, Khorana M, et al. Use of high titer RSV immunoglobulin (RI-001-RSV-IVIG) in immunocompromised adults. c.eqcdn.com [Internet]. [cited 2018 Jul 4]; Available from: http://c.eqcdn.com/_99eedb32d1a30f29209f897dab7e89f2/admabiologics/db/150/1731/file/ADMA+IDSA+compassionate+use+POSTER.pdf
- Falsey AR, Koval C, DeVincenzo JP, et al. Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immunocompromised persons. Transpl Infect Dis. 2017;19(2):1–8.
- Wasserman RL, Lumry W, Harris J, et al. Efficacy, safety, and pharmacokinetics of a new 10 % liquid intravenous immunoglobulin containing high titer neutralizing antibody to rsv and other respiratory viruses in subjects with primary immunodeficiency disease. J Clin Immunol [Internet]. 2016 Aug ;36(6):590–599. cited 2018 Jul 4 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27324887
- Orange JS, Du W, Falsey AR. Therapeutic immunoglobulin selected for high antibody titer to rsv also contains high antibody titers to other respiratory viruses. Front Immunol [Internet]. 2015;6:431. [cited 2018 Jul 4]. Available from http://www.ncbi.nlm.nih.gov/pubmed/26379667
- Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol [Internet]. 1969 Apr 1 [cited 2018 Jan 11];89(4):422–434.
- Villafana T, Falloon J, Griffin MP, et al. Passive and active immunization against respiratory syncytial virus for the young and old. Expert Rev Vaccines [Internet]. 2017 Jul 3 cited 2018 Jul 5;16(7):737–749. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28525961
- Karron RA, Buchholz UJ, Collins PL. Live-attenuated respiratory syncytial virus vaccines. Berlin, Heidelberg: Springer; 2013. cited 2017 Nov 6259–284. DOI: 10.1007/978-3-642-38919-1_13
- Jorquera PA, Tripp RA. Respiratory syncytial virus: prospects for new and emerging therapeutics. Expert Rev Respir Med [Internet]. 2017 Aug 3 [cited 2017 Oct 17];11(8):609–615.
- Hall CB, Walsh EE, Long CE, et al. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis [Internet]. 1991 Apr [cited 2017 Nov 11];163(4):693–698. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2010624
- Nacoti M, Colombo J, Fochi O, et al. Sevoflurane improves respiratory mechanics and gas exchange in a case series of infants with severe bronchiolitis-induced acute respiratory distress syndrome. Clin Case Reports [Internet]. 2018 May ;6(5):920–925. cited 2018 Jun 26 Available from: http://www.ncbi.nlm.nih.gov/pubmed/29744088
- Jordan PC, Stevens SK, Deval J. Nucleosides for the treatment of respiratory RNA virus infections. Antivir Chem Chemother [Internet]. 2018;26:2040206618764483. [cited 2018 Jun 26]. Available from http://www.ncbi.nlm.nih.gov/pubmed/29562753
- Palmu S, Mecklin M, Heikkilä P, et al. National treatment guidelines decreased the use of racemic adrenaline for bronchiolitis in four Finnish university hospitals. Acta Paediatr [Internet]. 2018 May 31 [cited 2018 Jun 26]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29752817
- Jiménez García R, Andina Martínez D, Palomo Guerra B, et al. [Impact of a new acute bronchiolitis protocol on clinical practice]. An Pediatr (Barc) [Internet]. 2018 Apr 20. cited 2018 Jun 26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29685831
- Breakell R, Thorndyke B, Clennett J, et al. Reducing unnecessary chest X-rays, antibiotics and bronchodilators through implementation of the NICE bronchiolitis guideline. Eur J Pediatr [Internet]. 2018 Jan 28 cited 2018 Jun 25;177(1):47–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29080051